StockNews.AI
URGN
StockNews.AI
114 days

New Long-Term Follow-Up Data from OPTIMA II Study of UGN-102 Demonstrates Median Duration of Response of Two Years in Patients with LG-IR-NMIBC

1. UGN-102 shows a 24.2-month sustained response in Phase 2b study. 2. The data supports UroGen's commitment to cancer treatment innovation.

2m saved
Insight
Article

FAQ

Why Bullish?

Strong clinical results can enhance investor confidence and support stock price growth. Historical rises often follow positive clinical trial data releases in biotech.

How important is it?

The trial data presents significant implications for UroGen's product pipeline and market position, likely moving investor sentiment positively.

Why Short Term?

Positive trial data typically leads to immediate market reactions, affecting stock prices quickly. For instance, similar outcomes have seen price surges within weeks.

Related Companies

KMPHXLRNTLSA
PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced new data from the OPTIMA II Phase 2b study of UGN‑102 (mitomycin) for intravesical solution demonstrate clinically meaningful two-year duration of response (24.2 months) by Kaplan-Meier analysis. UGN-102 is UroGen's sustained-release formulation of mitomycin being developed for the tre.

Related News